It is also noteworthy that FGFR4 represents an attractive new therapeutic target in cancer treatment, and several small kinase inhibitors are in preclinical and clinical development for the treatment of various cancers, including mCRC [36]. This evidence concerns the gene FGFR4 and cancer.